Cisplatin (CIS) Administered As Dry Powder for Inhalation (DPI) in Patients with Stage IV Non-Small Cell Lung Cancer

The combination of chemotherapy and immunotherapy shows promising results in terms of overall survival (OS) and progression-free survival (PFS) for the treatment of first-line stage IV non-small cell lung cancer (NSCLC) patients, leading to such combinations becoming a real backbone of the Standard of Care (SoC) for NSCLC patients. However, conventional chemotherapy's severe systemic toxicities represent a limiting factor in terms of administered dose and frequency. Administration of cisplatin by inhalation (pulmonary route) is a promising additional approach that may overcome the limitations

Trial Details

NCT ID
NCT06896890
Phase
PHASE1 / PHASE2
Sponsor
Inhatarget Therapeutics
Status
RECRUITING
Cancer Type
Lung Cancer
Interventions
  • CIS-DPI
Locations (sample)
  • Brussels, Belgium|50.85045,4.34878
  • Charleroi, Belgium|50.41136,4.44448
  • Jolimont, Belgium|50.4732,4.22508
  • Kortrijk, Belgium|50.82803,3.26487
  • Liège, Belgium|50.63373,5.56749

Key Eligibility Criteria

  • The patient must be ≥18 years of age at the time of signing the informed concent form (ICF).
  • The patient must have a pathologically or cytologically confirmed Stage IV NSCLC that could be treated with pembrolizumab alone or combined with ca…
  • The patient must have measurable disease according to RECIST 1.1.
  • The patient must be treatment naïve for stage IV NSCLC at the time of study enrolment. Patients having received, at least 6 months before D1, plati…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lung Cancer Trials on Trialify →